Ausgabe 5/2005
Inhalt (13 Artikel)
S-phase modulation by irinotecan: pilot studies in advanced solid tumors
N. Ramnath, N. Khushalani, K. Toth, A. M. Litwin, M. E. Intengan, H. K. Slocum, L. Pendyala, P. F. Smith, C. C. Stewart, J. L. Hoffman, M. M. Javle, J. Berdzik, P. J. Creaven, Y. M. Rustum
Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft
F. R. Luo, Z. Yang, H. Dong, A. Camuso, K. McGlinchey, K. Fager, C. Flefleh, D. Kan, I. Inigo, S. Castaneda, W. C. Rose, R. A. Kramer, R. Wild, F. Y. Lee
Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents
Ayako Yawata, Su-Ryang Kim, Atsuko Miyajima, Takashi Kubo, Seiichi Ishida, Yoshiro Saito, Yukiko Nakajima, Noriko Katori, Yoshiaki Matsumoto, Masamichi Fukuoka, Yasuo Ohno, Shogo Ozawa, Jun-ichi Sawada
Augmenting tumor sensitivity to topotecan by transient hypoxia
Eva L. Lund, Lasse T. Hansen, Paul E. G. Kristjansen
Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study
P. Comella, B. Massidda, S. Palmeri, A. Farris, L. De Lucia, D. Natale, L. Maiorino, S. Tafuto, G. De. Cataldis, R. Casaretti
Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study
G. P. Stathopoulos, D. Tsavdaridis, N. A. Malamos, S. K. Rigatos, Ch. Kosmas, N. Pergantas, J. G. Stathopoulos, J. Xynotroulas
Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation
Josephia R. Muindi, Douglas M. Potter, Yibing Peng, Candace S. Johnson, Donald L. Trump
Investigation of the influence of modulation of P-glycoprotein by a multiple dosing regimen of tamoxifen on the pharmacokinetics and toxicodynamics of doxorubicin
Ramin Darvari, Mehdi Boroujerdi
Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma
Ian S. Zagon, Jeffrey R. Jaglowski, Michael F. Verderame, Jill P. Smith, Alphonse E. Leure-duPree, Patricia J. McLaughlin
Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer
E. Briasoulis, E. Samantas, H. Kalofonos, D. Skarlos, T. Makatsoris, C. Christodoulou, G. Fountzilas, A. Bamias, M.A. Dimopoulos, P. Kosmidis, N. Pavlidis
Spectrophotometric investigation of the chemical compatibility of the anticancer drugs irinotecan-HCl and epirubicin-HCl in the same infusion solution
Filiz Arioz Ozdemir, Beril Anilanmert, Mursit Pekin
Magnesium depletion enhances cisplatin-induced nephrotoxicity.
H. Lajer, M. Kristensen, H. H. Hansen, S. Nielsen, J. Frøkiær, L. F. Østergaard, S. Christensen, G. Daugaard, T. E. N. Jonassen
Hyperacetylation enhances the growth-inhibitory effect of all-trans retinoic acid by the restoration of retinoic acid receptor β expression in head and neck squamous carcinoma (HNSCC) cells
Young Mi Whang, Eun Jung Choi, Jae Hong Seo, Jun Suk Kim, Young Do Yoo, Yeul Hong Kim